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56% complained frequent and debilitating episodes of migraine with
aura before treatment.
Percutaneous PFO closure was performed under local anesthesia
with intracardiac ultrasound guidance (9 MHz Ultra ICE, Boston Sci-
entiﬁc Corporation, San Jose, California) to optimize the positioning
of the devices. The PFO devices used up to now are: Amplatzer® (4
patients 11.8%), Cardia® (4 patients 11.8%), and Figulla® Flex PFO
Occluder (26 patients 76.4%). All patients were then treated with
acetylsalicylic acid 100–325 mg/die and Ticlopidine 500 mg/die orPatent foramen ovale (PFO) is an abnormal communication between
the right and the left atrium due to an incomplete fusion between
septum primum and septum secundum [1]. It involves 25–30% of
the general population [2]. PFO is often associated to cryptogenic ce-
rebral vascular accident (CVA) [3,4] and migraine with aura [5]. PFO
can be also associated with other anatomical abnormalities (Chiari
network, septal aneurysm, eustachian valve) which can increase
the shunt [1].
As the prevailing increase of PFO percutaneous interventions, we
found interesting to assess the “Quality of Life” after percutaneous
closure, intending to describe the state of physical, psychological
and social well-being.
In our center between July 2009 and July 2012, the percutaneous
closure of PFO was performed in 34 patients: 20 women (58.8%)
and 14 men (41.2%); mean age 46±9.67. The diagnosis of right to
left shunt was achieved by the bubble test (9 ml of saline and 1 ml
of air) with the transcranial Doppler (TCDc). Then a trans-thoracic
echocardiography (TTE) conﬁrmed the right to left shunt of
micro-bubbles and allowed to ﬁnd out the presence of atrial septal
aneurysm (ASA) and other anatomical anomalies such as the Chiari
network and the eustachian valve. The anatomical and functional
characteristics of PFO were then better studied with transesophageal
echocardiography (TEE)-(Fig. 1).
The indications employed for percutaneous treatment, after careful
echocardiographic studies andneurological consults, consist in the occur-
rence of ischemic events TIA/STROKE, classiﬁed as cryptogenic nature
(65% of our treated patients), often recurrent, or the presence of multiple
cerebral ischemic lesions detected with MRI, even if asymptomatic, forPalermo Sicily/Italy. Tel.: +39
. Kauroo).
Ltd. All rights reserved.
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013.01.015which no valid etiopathogenetic cause could be identiﬁed. Moreover
Clopidogrel 75 mg/die for the ﬁrst six months and then only
acetylsalicylic acid for another 6 months.
The follow-up includes a Holter-ECG (7 days after closure) and
then programmed controls: TTE at 1 and 3 months, TTE+TCDc at
6 months and at 1 year.
After informed consent, our treated patients were subjected to a
validated questionnaire, “Quality of Life” (QoL) SF 36 V1 standard
[6], administered before PFO closure and then after 6 months. The
questionnaire is a self-compile generic test on quality of life studying
multiple aspects of the psycho-physical well-being of the subject
through 36 questions. The result obtained from the responses is rep-
resented by 8 scales, which is a quantiﬁcation of a speciﬁc aspect of
health status.Fig. 1. Echocardiography ultrasound characteristics.
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Table 1
Pre/post treatment mean values and standard deviations.
Mean pre-treatment Mean post-treatment Standard dev. pre-treatment Standard dev. post treatment Paired probability
Physical activity 66.72 85.34 28.32 19.31 p=0.001
Physical role limitation 42.24 81.89 43.35 29.04 p=0.0001
Migraine 59.45 80.55 27.82 24.47 p=0.0001
General health 48.93 71.62 22.58 24.3 pb0.0001
Vitality 52.93 73.2 23.99 21.7 pb0.0001
Social activities 60.82 82.24 27.65 21.57 p=0.0001
Emotional role limitation 49.27 82.24 42.37 22.5 pb0.0001
Mental health 56.27 82.24 22.24 17.85 pb0.0001
2 S. Evola et al. / International Journal of Cardiology xxx (2013) xxx–xxxAmong our 34 treated patients, 4 were excluded from the study
for recent closure; 29 patients were subjected to QoL questionnaire
while n=1 was unavailable.
The mean values obtained on different ﬁelds, from the analysis of
the questionnaires, before and after treatment administration, were
compared using the Student t-test for paired samples, in order to as-
sess the statistical signiﬁcance of improvements on quality of life. The
obtained values are expressed as mean±1 SD. A p value of b0.05 was
considered statistically signiﬁcant.
The procedure was successfully performed in 34 treated patients.
No complications were recorded during the procedure. The presence
of new-onset atrial ﬁbrillation (AF) was excluded. A closure rate of
86.6% was obtained and no cerebrovascular symptomatic events oc-
curred in treated patients, until now. The QoL SF-36 questionnaire
reported a positive impact of the procedure on the quality of life by
re-appropriation of normal daily activities; also from the psychologi-
cal point of view. The comparison of the mean values obtained from
the analysis on different ﬁelds of the questionnaire, before and after
treatment, has suggested a statistically signiﬁcant improvement in
quality of life (Table 1).
This result is reasonably related to the improvement of migraine
patients which were conﬁned below all aspects. Among our 19 pa-
tients which were affected from severe migraine with aura, 94.7%
had in fact a signiﬁcant beneﬁt in health, due to an important reduc-
tion of the migraine frequency and severity or even their interruption
(p=0.0001).
In patients with cryptogenic stroke and PFO, the percutaneous clo-
sure treatment represents a possible and effective procedure and a pos-
sible alternative to the only antiplatelet or anticoagulant medical
therapy conducted for a lifetime [7,8], even if the ﬁrst randomized con-
trolled trial, CLOSURE I,has not demonstrated the superiority of the per-
cutaneous treatment against the medical therapy [9]. In our center the
percutaneous technique was initiated relatively recently, however our
results are encouraging. We considered only the presence of CVA as
the main indication for percutaneous treatment of PFO while patients
with migraine with aura were treated only with a medical therapy,
according to the 2010 Italian SPREAD (Stroke Prevention and Educa-
tional Awareness Diffusion) guidelines (VI edition).
Although migraine with aura does not represent an indication for
percutaneous closure, and the results of the MIST I [10] were deﬁnite-Please cite this article as: Evola S, et al, The percutaneous closure of pat
(2013), http://dx.doi.org/10.1016/j.ijcard.2013.01.015ly lower than expected, the ﬁnding of a clinical improvement of this
disease, bodes well for a substantial improvement in quality of life
for these patients. Also the psychological aspect should not be
underestimated. The prospect of an effective secondary prevention
of ischemic recurrences, through a permanent treatment, could cer-
tainly contribute to improve the quality of life and interpersonal rela-
tionships of these subjects.
The percutaneous closure of the PFO seems to lead a good impact
on the quality of life compared to the life condition prior the closure
treatment. Certainly, further studies with larger cases are necessary
to assess the real beneﬁt of PFO percutaneous closure. Therefore
we suggest to use common sense in the choice and selection of pa-
tients for the indication of percutaneous closure, and particularly to
take in more consideration also those with the only migraine with
aura.
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